<h4>Background</h4>The clinical efficacy of the BCL-2 inhibitor venetoclax in acute myeloid leukemia (AML) is significantly undermined by the frequent emergence of drug resistance, which precipitates disease progression and poor patient outcomes. This evidence concerns the gene BCL2 and acute myeloid leukemia.